Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine.
We conducted an extended follow-up study (March 2006-May 2008) to assess the longer term efficacy of a prophylactic monovalent human papillomavirus (HPV) type 16 L1 virus-like particle vaccine in women (n=290) who had enrolled in a randomized controlled trial of this vaccine (October 1998-November 1999) in Seattle and remained HPV-16 DNA negative during the course of that trial. During the extended follow-up period, in the per-protocol susceptible population, none of the vaccine recipients was found to be infected with HPV-16 or developed HPV-16-related cervical lesions; among placebo recipients, 6 women were found to be infected with HPV-16 (vaccine efficacy [VE]=100%; 95% confidence interval [CI]: 29-100%) and 3 women developed HPV-16-related cervical lesions (VE=100%; 95% CI: <0-100%). Approximately 86% of vaccine recipients remained HPV-16 competitive Luminex immunoassay seropositive at an average of 8.5 years of follow-up. During the combined original trial and extended follow-up period, in the intention-to-treat population, 20 and 22 women developed any cervical lesion regardless of HPV type among the vaccine and placebo recipients, respectively (VE=15%; 95% CI: <0-56%). The results suggest that this monovalent HPV-16 vaccine remains efficacious through 8.5 years after its administration.
Rowhani-Rahbar
Ali
A
Department of Epidemiology, University of Washington, Seattle, WA 98125, USA. rowhani@u.washington.edu
Mao
Constance
C
Hughes
James P
JP
Alvarez
Frances B
FB
Bryan
Janine T
JT
Hawes
Stephen E
SE
Weiss
Noel S
NS
Koutsky
Laura A
LA
D000293:Adolescent; D036022:Capsid Proteins / Q000276:immunology*; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D010919:Placebos / Q000008:administration & dosage; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*; D022721:Vaccines, Virosome / Q000276:immunology; D055815:Young Adult
D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D010919:Placebos; D022721:Vaccines, Virosome; C063317:L1 protein, Human papillomavirus type 16